Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Staining of p53 and PARP1 in breast cancer TMAs and comparison with the TCGA database indicated a higher double-positive signal in basal-like breast cancer than in Luminal A or Luminal B subtypes.
|
31776133 |
2020 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The mechanism and efficacy of PARP inhibitors have been well studied in some cancers, especially homologous recombination (HR)-deficient ovarian cancer and breast cancer, yet such studies are still relatively fewer in lung cancer.
|
31753490 |
2020 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compound 81, an isoform-selective PARP-1/-2 (IC<sub>50</sub> = 30 nM/2 nM) inhibitor, demonstrated selective cytotoxic effect toward breast cancer gene 1 ( BRCA1)-deficient cells compared to isogenic BRCA1-proficient cells.
|
31042381 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of the DNA repair protein PARP1 has had little efficacy as a single agent in breast cancer outside of studies restricted to patients with BRCA mutations; however, PARP1 inhibition (PARPi) may lead to the radiosensitization of aggressive tumor types.
|
31413177 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The use of PARP inhibitors in other cancers with homologous recombination repair deficiencies, such as breast cancer and prostate cancer, is gradually evolving as well, including their use in the neoadjuvant and adjuvant settings.
|
28583748 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The exposure of breast cancer cells to the lactone was associated with a depolarization in mitochondrial membrane potential, and cleavage of caspase and PARP.
|
31784542 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
To this end, by encapsulating the miR-451 mimic and PARP1 inhibitor in the same cationic liposome, we examined the potential of enhancing the response of PARP1 inhibition on BRCA1-deficient breast cancer by regulating the PI3K pathway.
|
30873673 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
|
31322269 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this scenario, the goal of this study was to identify novel prototypes of PARP-1 inhibitors for the development of antitumor therapeutics to treat breast cancer.
|
31442685 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors have been proven clinically efficacious in platinum-responsive ovarian cancer regardless of BRCA1/2 status and in breast cancers with germline BRCA1/2 mutation.
|
30755715 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors represent one of the successful models of translational research in this area and clinical data showed high efficacy and reasonable toxicity with these agents in patients with breast cancer and BRCA mutation.
|
31181965 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
PARP1 inhibitors (PARPi) are currently used in the clinic for the treatment of ovarian and breast cancers, yet their therapeutic efficacy against hepatocellular carcinoma (HCC) has been disappointing.
|
30573522 |
2019 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Among Iranian women, the association between PARP1 polymorphisms and BC was never studied before so in this case-control study, the genetic association of three SNPs (rs1136410, rs907187 and rs4653734) was analyzed with susceptibility to BC.
|
31288058 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors have recently been approved as monotherapies for the treatment of recurrent ovarian cancer and metastatic <i>BRCA</i>-associated breast cancer, and ongoing studies are exploring additional indications and combinations with other agents.
|
30429212 |
2019 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Targeting DNA damage and synthetic lethality strategies with PARP inhibitors for breast cancer patients harboring BRCA mutation.
|
31151842 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although PARP1 was found at BRG1 positive/H3K27ac negative promoters of highly expressed genes in a transformed breast cancer cell line, its transcriptional activity was limited to genes simultaneously controlled by BRG1 and EP300, indicating that the ADP-ribosylation of EP300 plays a dominant role in the regulation of BRG1-EP300-driven transcription.
|
31614656 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of GALNT6 in breast cancer cell attenuated the protein expression of PCNA, cyclin D1, C-myc and β-catenin, and increased the expression of E-cadherin, caspase 3 and cleaved PARP1.
|
30662357 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In breast cancer treatment the introduction of PARP inhibitors has begun.
|
30520757 |
2019 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, biological rationale, preclinical, and clinical data support the prominent role of CDK 4/6 inhibitors plus endocrine therapy, even in combination with PARP inhibitors, in the treatment of BRCA-mutated, ER-positive breast cancers.
|
31456944 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
We hypothesized that PARP1 activity mediated tamoxifen resistance in ERα-positive breast cancer and that combining the antiestrogen tamoxifen with a PARP1 inhibitor (PARPi) would sensitize tamoxifen resistant cells to tamoxifen therapy.
|
30621214 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
A Comparative Study of the Anticancer Activity and PARP-1 Inhibiting Effect of Benzofuran-Pyrazole Scaffold and Its Nano-Sized Particles in Human Breast Cancer Cells.
|
31261939 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The data provide insight into the mechanism of action of PARP inhibitors in <i>BRCA</i>-associated breast cancer.<i>This article is highlighted in the In This Issue feature, p. 681</i>.
|
31015319 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response.
|
30232143 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly, CDK12 protein absence was associated with reduced expression of a number of DDR proteins including ATR, Ku70/Ku80, PARP1, DNA-PK, and γH2AX, suggesting a novel mechanism of CDK12-associated DDR dysregulation in breast cancer.
|
29133620 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Resurrection of PARP Inhibitors in Breast Cancer.
|
30181424 |
2018 |